BTIG reiterates Buy rating on Jade Biosciences, $77 price target

What happened

BTIG reiterated its Buy rating on Jade Biosciences stock with a $77 price target. That target implies 431.0% upside from the October 26 close of $14.50. BTIG cited strong Phase 1 data for JADE101, which showed about a 70% reduction in IgA levels.

Confirmed

Global impact / market context

If JADE101's Phase 1 results hold up in larger trials, the drug could become a competitive treatment for immunoglobulin A nephropathy (IgAN), which is a kidney disease. A higher share of that market could lift future revenue and support the stock's re-rating toward BTIG's target.

Analyst inference

Price targets on Jade Biosciences from three recent analyst notes range from $47 to $77, so BTIG sits at the high end. This suggests analysts see large potential but disagree on timing and risk, and upcoming pipeline data in 2026 and 2027 could shift those views.

Analyst inference

What to watch

1. Jade Biosciences plans upcoming data releases from its JADE201 and JADE301 candidates in 2026 and 2027, which could further validate the company's pipeline and support its stock value. Confirmed
2. BTIG's note implies that a streamlined Phase 3 trial timeline for JADE101 could speed regulatory progress; investors should watch whether the company confirms enrollment and submission dates for that program. Proposed
3. Watch whether JADE101's roughly 70% IgA reduction is reproduced in later-stage trials; weaker results would undercut the efficacy story that underpins BTIG's $77 target and could narrow analyst price targets. Analyst inference

Evidence

• Original source link unavailable